Shanghai Haohai Biological Technology Co Ltd 2020 AR2
The report outlines the financial and operational performance of Shanghai Haohai Biological Technology Co., Ltd. for the fiscal year 2020. Despite the significant negative impact of the COVID-19 pandemic on its product lines, particularly in the first quarter, the company experienced a recovery in the second half of the year, recording a total revenue of RMB 1,324.43 million. The company continued to invest in research and development, focusing on ophthalmology and medical aesthetics, with R&D expenses reaching RMB 126.47 million. Additionally, the report highlights the company's commitment to corporate social responsibility, including environmental protection compliance and employee training programs.
Company: Shanghai Haohai Biological Technology Co Ltd
Sector: Manufacturing
Country: China
Year: 2020
Type: AR2
Pages: 189
Back to company
Shanghai Haohai Biological Technology Co Ltd
Annual Report
The report outlines the financial and operational performance of Shanghai Haohai Biological Technology Co., Ltd. for the fiscal year 2020. Despite the significant negative impact of the COVID-19 pandemic on its product lines, particularly in the first quarter, the company experienced a recovery in the second half of the year, recording a total revenue of RMB 1,324.43 million. The company continued to invest in research and development, focusing on ophthalmology and medical aesthetics, with R&D expenses reaching RMB 126.47 million. Additionally, the report highlights the company's commitment to corporate social responsibility, including environmental protection compliance and employee training programs.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Jan 1, 2020 - Dec 31, 2020
Fiscal Year
2020
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees